Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.83 |
| ▸ | DRD3 | P35462 | 14/20 | 0.83 |
| ▸ | HTR2A | P28223 | 3/20 | 0.63 |
| ▸ | DRD4 | P21917 | 3/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5366724 | 0.98 | DRD2 (0.81) | DRD2DRD3HTR2ADRD4SLC6A2 | |
| SCHEMBL1193610 | 0.95 | DRD2 (0.81) | DRD2DRD3HTR2ADRD4SLC6A2 | |
| SCHEMBL1193545 | 0.91 | DRD2 (1.00) | DRD2DRD3HTR2ADRD4SLC6A2 | |
| SCHEMBL9559590 | 0.89 | KDM4E (0.68) | DRD2DRD3DRD4HTR1AADRA1A | |
| SCHEMBL14494878 | 0.86 | DRD2 (0.76) | DRD2DRD3HTR2ADRD4SLC6A2 | |
| SCHEMBL29785752 | 0.86 | DRD2 (0.76) | DRD2DRD3HTR2ADRD4SLC6A2 | |
| SCHEMBL12441074 | 0.85 | DRD2 (1.00) | DRD2DRD3HTR2ADRD4SLC6A2 | |
| SCHEMBL31322363 | 0.85 | DRD2 (0.74) | DRD2DRD3HTR2ADRD4SLC6A2 | |
| SCHEMBL2216581 | 0.85 | DRD2 (0.74) | DRD2DRD3HTR2ADRD4SLC6A2 | |
| SCHEMBL14494808 | 0.85 | DRD2 (0.74) | DRD2DRD3HTR2ADRD4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220060-B1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES | MOTAC NEUROSCIENCE LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-8389555-B2 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110046153-A1 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2220060-A1 | MEDICAMENTS | Motac Neuroscience Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| EP-2162135-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009056805-A1 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | DRD2 26/4885DRD3 64/4885HTR2A 32/4885 |
| US-20110046153-A1 | Medicaments | MTNR1A, SIGMAR1, OPRK1 | DRD2 16/4885DRD3 41/4885HTR2A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.